RxDoctor Payments Data

London McKenna

Family · Plains, PANPI 1275141848

Payments from drug & device makers

$6,710in general payments, 2019–2025

Across 202 payments — averaging $33.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Si-bone, Inc.$1K
  • Boston Scientific$1K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$881
  • Collegium Pharmaceutical, Inc.$436
  • Averitas Pharma Inc.$369
  • Curonix LLC$365
  • plus $2K from 20 others

What the payments were for

  • Travel & lodging$1,72926%
  • Food & beverage$4,98174%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,710 in reported general payments places this provider in the 95th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,956
Medicare patients
191
Services billed
2,147

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BelbucaBuprenorphine Hcl61$46,275
RelistorMethylnaltrexone Bromide14$32,525
OxycontinOxycodone Hcl34$24,101
Xtampza ErOxycodone Myristate32$15,398
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$13,655
Buprenorphine29$11,036
Fentanyl41$6,709
RoxicodoneOxycodone Hcl11$6,235
Tizanidine Hcl290$4,408
Gabapentin171$3,139
Tramadol Hcl144$1,493
Morphine Sulfate ErMorphine Sulfate19$1,410
Methocarbamol36$702
Cyclobenzaprine Hcl73$648
Meloxicam193$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$436$61,67393 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$881$32,52514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,717 family providers in Pennsylvania.

Other family in Plains

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →